Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

Clonotypic Peptide Mass Spectrometry to Define Functional Cure in Patients with Multiple Myeloma Undergoing Maintenance Cessation

Benjamin A Derman, Tadeusz Kubicki, Jennifer H Cooperrider, Anna Pula, Ken Jiang, Mariel Coradin, Ravleen Virdi, Fionn McLoughlin, Luciano Di Stefano, Vincent Bonifay, Caroline Rougé Dubroc, Andrzej J Jakubowiak

Blood (2024) 144 (Supplement 1): 1949.

https://doi.org/10.1182/blood-2024-203566

Published: 2024

Journal Articles

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Blood (2024) 144 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2024-198499

Published: 2024

Journal Articles

Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up

Michael R Bishop, Jacalyn Rosenblatt, Binod Dhakal, Noopur Raje, Daniella Cook, Mahmoud R. Gaballa, Estelle Emmanuel-Alejandro, Danielle Nissen, Kamalika Banerjee, Rebecca J Chan, Ana Kostic, Christopher R. Heery, Tim Welliver, David Avigan, Andrzej J Jakubowiak, Matthew Frigault

Blood (2024) 144 (Supplement 1): 4825.

https://doi.org/10.1182/blood-2024-201080

Published: 2024

Journal Articles

Identifying 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA and Treatment Response in Multiple Myeloma with a Multi-Step Machine Learning Approach

Bei Wang, Benjamin A Derman, Zhou Zhang, Krissana Kowitwanich, John F. Cursio, Daniel Appelbaum, Chuan He, Wei Zhang, Andrzej J Jakubowiak, Brian Chiu

Blood (2024) 144 (Supplement 1): 3336.

https://doi.org/10.1182/blood-2024-204305

Published: 2024

Journal Articles

Prevalence and Clinical Implications of Germline Variants in Multiple Myeloma Patients

Tadeusz Kubicki, Kaina Millan, Anna Pula, Henry Raeder, Quinn Hauck, Manoj Bhagwat, Jude Barton, Eyitayo Awe, Soma Das, Daniela Del Gaudio, Sulin Wu, Frank Wen, Jennifer H Cooperrider, Benjamin A Derman, Andrzej J Jakubowiak, Michael W Drazer

Blood (2024) 144 (Supplement 1): 3335.

https://doi.org/10.1182/blood-2024-207445

Published: 2024

Journal Articles

Association between Brain-to-Vein Time and Disease Characteristics and Outcomes for Commercial CAR T-Cell Therapy in Multiple Myeloma

Tyra K Grischke, Benjamin A Derman, Andrzej J Jakubowiak, Jennifer H Cooperrider

Blood (2024) 144 (Supplement 1): 7857.

https://doi.org/10.1182/blood-2024-210949

Published: 2024

Journal Articles

Evolution of Clonal Hematopoiesis after Discontinuation of Therapy for Multiple

Jennifer H Cooperrider, Diren Arda Arda Karaoglu, Tadeusz Kubicki, Ken Jiang, Ella Postich, Kathryn Kimi Shimamoto, Olivia Arnold, Aubrianna Ramsland, Anna Pula, Jommel Macaraeg, Andrzej J Jakubowiak, Benjamin A Derman, Caner Saygin

Blood (2024) 144 (Supplement 1): 253.

https://doi.org/10.1182/blood-2024-208256

Published: 2024

Journal Articles

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Blood (2024) 144 (9): 955–963.

https://doi.org/10.1182/blood.2024024041

Published: 2024

Includes: Supplemental data

Journal Articles

Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

Ben A Derman, Tadeusz Kubicki, Heidi Simmons, Aimaz Afrough, Jeffrey A. Zonder, David L. Grinblatt, Larry D. Anderson, Jr., Andrew Kin, Sunil Narula, Shayan Rayani, Sandeep Gurbuxani, Theodore Karrison, Ken Jiang, Ajay Major, Jennifer H Cooperrider, Allison P. Jacob, Andrzej J Jakubowiak

Blood (2023) 142 (Supplement 1): 1982.

https://doi.org/10.1182/blood-2023-182410

Published: 2023

Journal Articles

Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients

Matthew J. Frigault, Jacalyn Rosenblatt, Binod Dhakal, Noopur S. Raje, Daniella Cook, Mahmoud Gaballa, Estelle Emmanuel-Alejandro, Danielle Nissen, Kamalika C Banerjee, Anand Rotte, Christopher R Heery, David Avigan, Andrzej J Jakubowiak, Michael R. Bishop

Blood (2023) 142 (Supplement 1): 1023.

https://doi.org/10.1182/blood-2023-189761

Published: 2023

Journal Articles

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2023) 142 (Supplement 1): 4715.

https://doi.org/10.1182/blood-2023-189850

Published: 2023

Journal Articles

Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Andrzej J Jakubowiak, Sebastien Anguille, Lionel Karlin, Ajai Chari, Carolina Schinke, Leo Rasche, Jesus San-Miguel, Michela Campagna, Brandi W Hilder, Tara J Masterson, Xiang Qin, Thomas Renaud, Jaszianne Tolbert, Deeksha Vishwamitra, Sheri Skerget, Philippe Moreau

Blood (2023) 142 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2023-187242

Published: 2023

Journal Articles

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Blood (2023) 142 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2023-189537

Published: 2023

Journal Articles

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Blood (2023) 142 (Supplement 1): 340.

https://doi.org/10.1182/blood-2023-190209

Published: 2023

Journal Articles

Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)

Benjamin A Derman, Jennifer H Cooperrider, Jacalyn Rosenblatt, David Avigan, Murtuza M. Rampurwala, Ajay Major, Theodore Karrison, Ken Jiang, Tadeusz Kubicki, Andrzej J Jakubowiak

Blood (2023) 142 (Supplement 1): 4747.

https://doi.org/10.1182/blood-2023-185309

Published: 2023

Journal Articles

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Blood (2020) 136 (22): 2513–2523.

https://doi.org/10.1182/blood.2020007522

Published: 2020

Includes: Supplemental data

Journal Articles

Treatment with the Novel TOPK Inhibitor OTS514 Exhibits Potent Anti-Myeloma Activity in Pre-Clinical Models

Andrew Stefka, MS, David Johnson, Shaun Rosebeck, PhD, Jae-Hyun Park, DVM, PhD, Yusuke Nakamura, MD, Andrzej J. Jakubowiak, MD

Blood (2017) 130 (Supplement 1): 4415.

https://doi.org/10.1182/blood.V130.Suppl_1.4415.4415

Published: 2017

Journal Articles

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial

A. Keith Stewart, MBChB, MBA, David Siegel, MD PhD, Heinz Ludwig, MD, Thierry Facon, MD, Hartmut Goldschmidt, MD, Andrzej J. Jakubowiak, MD, Jesus F. San Miguel, MD, Mihaela Obreja, Julie Blaedel, Meletios A. Dimopoulos

Blood (2017) 130 (Supplement 1): 743.

https://doi.org/10.1182/blood.V130.Suppl_1.743.743

Published: 2017

Journal Articles

Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)

Blood (2017) 130 (Supplement 1): LBA-4.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-4.LBA-4

Published: 2017

Journal Articles

Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study

Ajai Chari, Saad Z Usmani, MD, Amrita Krishnan, MD, Sagar Lonial, MD, Raymond Comenzo, Kaida Wu, Jianping Wang, Parul Doshi, Brendan M Weiss, MD, Jordan Schecter, Andrzej J. Jakubowiak, MD

Blood (2017) 130 (Supplement 1): 3110.

https://doi.org/10.1182/blood.V130.Suppl_1.3110.3110

Published: 2017

NARROW

Clonotypic Peptide Mass Spectrometry to Define Functional Cure in Patients with Multiple Myeloma Undergoing Maintenance Cessation

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up

Identifying 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA and Treatment Response in Multiple Myeloma with a Multi-Step Machine Learning Approach

Prevalence and Clinical Implications of Germline Variants in Multiple Myeloma Patients

Association between Brain-to-Vein Time and Disease Characteristics and Outcomes for Commercial CAR T-Cell Therapy in Multiple Myeloma

Evolution of Clonal Hematopoiesis after Discontinuation of Therapy for Multiple

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Treatment with the Novel TOPK Inhibitor OTS514 Exhibits Potent Anti-Myeloma Activity in Pre-Clinical Models

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial

Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)

Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only